Literature DB >> 23065664

Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents.

Jess T Whitson1, W Matthew Petroll.   

Abstract

INTRODUCTION: This in-vitro study compared the toxicity of bimatoprost 0.01% containing benzalkonium chloride (BAK) 0.02% with other commercial BAK-free or BAK-containing prostaglandin analogs.
METHODS: Six test solutions were evaluated: travoprost 0.004% with polyquaternium-1 0.001% (PQ), PQ, bimatoprost 0.01% with BAK 0.02%, latanoprost 0.005% with BAK 0.02%, tafluprost 0.0015% preservative free (PF), and BAK 0.02%. Phosphate-buffered saline (PBS) was the live control and 70% methanol was the dead control. Confluent human corneal epithelial cells were incubated with test solutions (diluted 1:5 or 1:10 with PBS) or control solutions for 10 or 25 min, after which cells were fluorescently labeled to distinguish live and dead cells. Data were expressed as a percentage of PBS live-cell fluorescence for automated readouts. Live and dead cells were manually counted for numeric analyses.
RESULTS: For 1:5 and 1:10 dilutions using automated readout, cells exposed to bimatoprost with BAK, latanoprost with BAK, and BAK alone demonstrated significant reductions in the live cell signal compared with PBS, travoprost with PQ, and PQ alone (all P < 0.001). They also demonstrated significantly greater toxicity than tafluprost PF for 1:5 dilutions (all P < 0.001) and 1:10 dilutions (P ≤ 0.02), except for 1:10-diluted bimatoprost with BAK (P = 0.41). For 1:5 dilutions using manual cell count, cells exposed to bimatoprost with BAK demonstrated significant reductions in the percentage of live cells compared with PBS (P = 0.02). For 1:10 dilutions using manual cell count, cells exposed to bimatoprost with BAK, latanoprost with BAK, and BAK alone demonstrated significantly greater toxicity than PBS, travoprost with PQ, PQ alone, and tafluprost PF (all P ≤ 0.03). No significant differences were observed among PBS, travoprost with PQ, and PQ alone under any test conditions (P ≤ 0.63).
CONCLUSION: This study demonstrated that BAKcontaining solutions, including bimatoprost 0.01% with BAK, were toxic to human corneal epithelial cells, whereas BAK-free solutions showed little to no evidence of toxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065664     DOI: 10.1007/s12325-012-0057-1

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  5 in total

1.  Confocal microscopy of epithelial and langerhans cells of the cornea in patients using travoprost drops containing two different preservatives.

Authors:  László Marsovszky; Miklós D Resch; Zsuzsanna Visontai; János Németh
Journal:  Pathol Oncol Res       Date:  2014-03-13       Impact factor: 3.201

2.  A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.

Authors:  Norbert Pfeiffer; Carlo E Traverso; Katrin Lorenz; Ville Saarela; Johanna Liinamaa; Hannu Uusitalo; Yury Astakhov; Ernest Boiko; Auli Ropo
Journal:  Adv Ther       Date:  2014-12-02       Impact factor: 3.845

3.  Safety data on in situ gelling bimatoprost loaded nanovesicular formulations.

Authors:  Monika Yadav; Ana Guzman-Aranguez; Maria J Perez de Lara; Mandeep Singh; Joga Singh; Indu Pal Kaur
Journal:  Data Brief       Date:  2019-08-06

Review 4.  Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog.

Authors:  Yoshimi Niwano; Atsuo Iwasawa; Masahiko Ayaki
Journal:  Ophthalmol Eye Dis       Date:  2014-02-13

5.  The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.

Authors:  Ranjan Malhotra; Stacey Ackerman; Lynne S Gearinger; Timothy W Morris; Catherine Allaire
Journal:  Drugs R D       Date:  2013-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.